world congress on osteoporosis, osteoarthritis and ... · malaga, spain 2016 april 14 - 17...

www.wco-iof-esceo.org | #OsteoCongressOrganized by Sinklar Conference Management B.V.

MALAGA, Spain

2016

April 14 to 17

PALACIO DE FERIASY CONGRESOSDE MALAGA

WORLD CONGRESS ON OSTEOPOROSIS,OSTEOARTHRITIS AND MUSCULOSKELETAL DISEASES

MALAGA, Spain2016 April 14 - 17

2 WCO-IOF-ESCEO 2016 - MALAGA, SPAIN - PROGRAMME

CONGRESS INFORMATIONEvent

April 14-17, 2016 WORLD CONGRESS ON OSTEOPOROSIS,

OSTEOARTHRITIS AND MUSCULOSKELETAL DISEASES

VenuePalacio de Ferias y Congresos de Malaga

Avenida Ortega y Gasset, 201 29006 Malaga, Spain Tel: +34 952 045 500

www.fycma.com

OrganizerSinklar Conference Management Hogehilweg, 7K 1101CA Amsterdam Zuidoost, Netherlands [email protected]

SecretariatHumacom Rue Renier, 9 4800 Verviers, Belgium Tel: +32 87 852 652 Fax: +32 87 315 003 [email protected] www.humacom.com

Congress Websitewww.wco-iof-esceo.org

REGISTRATIONEarly Registration

< Dec 4, 2015Pre-registration

< Dec 4, 2015 - Mar 4, 2016 > On Site

IOF Member 735 € 795 € 995 €

Non-Member 795 € 895 € 995 €

Student 250 € 270 € 300 €

Registration cancellation: within June 30, 2015, 50% of the registration fee will be refunded.

After this date, no refund will be possible for cancellations.

ABSTRACTSSubmission Period for AbstractsOctober 1, 2015 to January 15, 2016

Notification to the contributorsFebruary 5, 2016

ACCREDITATIONSEuropeanThe WCO-IOF-ESCEO Malaga 2016 Congress was granted 15 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

AmericanEACCME credits can be converted to AMA credits for American delegates.

BelgianThe WCO-IOF-ESCEO Malaga 2016 Congress was granted 3 Belgian CME credits (INAMI/RIZIV) under the numbers 15025422, 15025901, 15025420 in category 6 “Ethics & Economy”. CME credits for the category 4 “International Meeting” are in process.

ItalianItalian Accreditation is in process

MALAGA, Spain2016 April 14 - 17

4 WCO-IOF-ESCEO 2016 - MALAGA, SPAIN - PROGRAMME

SCIENTIFIC INFORMATIONCongress Chairmen

Jean-Yves REGINSTER ESCEO President

John A. KANIS IOF President

Programme CommitteeCyrus COOPER

Chair, IOF Committee Scientific Advisors (CSA)

René RIZZOLI Chair, ESCEO Scientific Advisory Board (SAB)

John A. KANIS IOF President

Jean-Yves REGINSTER ESCEO President

Honorary Local Organizing Committee

Jorge CANNATA-ANDIAAlfonso CRUZ JENTOFT

Adolfo DIEZ PEREZJosé Antonio LÓPEZ TRIGO

Vincenzo MALAFARINAJordi MONFORTXavier NOGUES

ESCEO Scientific Advisory BoardDonato AGNUSDEIKristina AKESSONMaurice AUDRANJean-Jacques BODYAndrew BORGMary BOUXSEINMaria-Luisa BRANDIOlivier BRUYÈRENansa BURLETEtienne CAVALIERClaus CHRISTIANSENJuliet COMPSTONCyrus COOPERBernard CORTETJean-Pierre DEVOGELAERAndrea GASPARIKNicholas HARVEYMickaël HILIGSMANNJohn A. KANISJean-Marc KAUFMANPaul LIPSRoman LORENCGeorge LYRITISJohanne MARTEL-PELLETIEREugene McCLOSKEYSocrates PAPAPOULOSKarel PAVELKAJean-Pierre PELLETIERJean-Yves REGINSTERJohann RINGERené RIZZOLIChristian ROUXPavel SZULCThierry THOMAS

March 23rd - 26th, 2017

Congress Organizer Sinklar Conference Management B.V.

Congress Secretariatwww.humacom.com

17.30 - 19.45Teatro Cervantes

WCO-IOF-ESCEO - OPENING CEREMONYWCO-IOF-ESCEO - OPENING CEREMONYChairpersons: John A. Kanis, Jean‑Yves Reginster

17.30Teatro Cervantes

Best clinical papers published in 2015René Rizzoli


Opening of the meetingCyrus Cooper


Regulatory perspectives of the development ofdrugs to be used in the management of frailty andsarcopenia

Francesca Cerreta (European Medicines Agency – London)


Rethinking healthy ageing and the concept offunctioning

Islene Araujo de Carvalho (World Health Organization – Geneva)


HONORARY LECTUREExpression of human body in Picasso's work

José Lebrero Stals (Artistic Director, Museo Picasso Malaga)


Presentation of the 2016 ESCEO Medal ofExcellence

Jean‑Yves Reginster


Presentation of the ESCEO-IOF Herbert FleischMedal


19.55 - 20.55Teatro Cervantes

INDUSTRY-SPONSORED WELCOME COCKTAILINDUSTRY-SPONSORED WELCOME COCKTAIL

6

08.00 - 09.00NON-SPONSORED SYMPOSIANON-SPONSORED SYMPOSIA

Meeting Room 1

Preventing future fractures: implementingFracture Liaison Services throughout the UK

Chairperson: Hilary Arden

- Model of support for FLS development - Hilary Arden

- Quality improvement - Jo Sayer

- Socioeconomic costs and benefits - Tim Jones

Meeting Room 2

Evaluation of Fracture Risk: beyond DXA andBTMs

Chairperson: Serge Ferrari

- Distal bone microstructure - Emmanuel Biver

- Circulating bone regulatory proteins (Sost, Rankl,postn, ...) - Roland D. Chapurlat

- Falls risk assessment - Andrea Trombetti

Meeting Room 3

Physical activity in treatment and prevention ofosteoporosis

Chairperson: Mark Lissens

- Introduction - Mark Lissens

- Importance of physical activity in primary,secondary and tertiary prevention of osteoporosis -Olivier Bruyère

- Can exercise interventions designed to reduce fallsimprove bone quality - Tash Masud

- Specific anti-osteoporotic interventions in patientsentering various types of rehabilitation programmes- Daniel Uebelhart

Meeting Room 4

Bioactive Collagen Peptides for theMaintenance and Improvement ofMusculoskeletal Health

Chairperson: Stephan Scharla

- Welcome and introductory presentation -Stephan Scharla

- Osteoarthritis / Osteoporosis - Steffen Oesser

- Sarcopenia - Daniel König

Meeting Room 5

Inflammatory arthritis and bone healthChairperson: Elaine M. Dennison

- Welcome & Introduction - Elaine M. Dennison

- Gout and bone health - Bo Abrahamsen

- HIV arthritis and bone health - Karen Walker‑Bone

- Novel ways of assessing the relationship betweeninflammatory arthritis and bone - Mark H. Edwards

- Discussion - Elaine M. Dennison

09.00 - 12.10Auditorium 1

SCIENTIFIC SESSION ISCIENTIFIC SESSION IChairpersons: John A. Kanis, Jean‑Yves Reginster

09.00Auditorium 1

Plenary Lecture 1Plenary Lecture 1 - The Qualities of Bone and Fracture Risk - Ego Seeman

09.30Auditorium 1

Oral communications selected from abstracts09.30Auditorium 1

OC1EFFECTS OF ABALOPARATIDE ON VERTEBRAL,NONVERTEBRAL, MAJOR OSTEOPOROTIC ANDCLINICAL FRACTURE INCIDENCE INPOSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS:RESULTS OF THE PHASE 3 ACTIVE TRIALPresenting author: L. A. FitzpatrickAuthors: P. Miller, F. Cosman, D. Black, E. Lau, C. A. F. Zerbini,B. J. Riis, C. Christiansen, G. Williams, M. Y. Hu, G. Hattersley

09.40Auditorium 1

OC2EIGHTEEN MONTHS OF TREATMENT WITHABALOPARATIDE FOLLOWED BY SIX MONTHS OFTREATMENT WITH ALENDRONATE INPOSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS:RESULTS OF THE ACTIVEXTEND TRIALPresenting author: S. FerrariAuthors: F. Cosman, P. Miller, G. Hattersley, G. Williams,M. Y. Hu, B. J. Riis, C. Christensen, L. A. Fitzpatrick

09.50Auditorium 1

OC3SUPERIOR GAINS IN BONE MINERAL DENSITY ANDESTIMATED STRENGTH AT THE HIP FORROMOSOZUMAB COMPARED WITH TERIPARATIDEIN WOMEN WITH POSTMENOPAUSALOSTEOPOROSIS TRANSITIONING FROMBISPHOSPHONATE THERAPY: RESULTS OF THEPHASE 3 OPEN-LABEL STRUCTURE STUDYPresenting author: J. MaloufAuthors: B. L. Langdahl, C. Libanati, D. B. Crittenden,M. A. Bolognese, J. P. Brown , N. S. Daizadeh, E. Dokoupilova,K. Engelke, J. S. Finkelstein, H. K. Genant, S. Goemaere,L. Hyldstrup, E. Jodar‑Gimeno, T. M. Keaveny, D. L. Kendler,P. L. Lakatos, J. Maddox, F. E. Massari, J. F. Molina,M. R. Ulla, A. Grauer

7

10.00Auditorium 1

OC4A RANDOMIZED DOUBLE-BLIND STUDY OFDENOSUMAB (DMAB) COMPARED WITHZOLEDRONIC ACID (ZOL) IN POSTMENOPAUSALWOMEN WITH OSTEOPOROSIS PREVIOUSLYTREATED WITH ORAL BISPHOSPHONATESPresenting author: P. MillerAuthors: N. Pannacciulli, J. P. Brown , E. Czerwinski,B. S. Nedergaard, M. A. Bolognese, J. Malouf, H. G. Bone,J.‑Y. Reginster, A. Singer, C. Wang, R. B. Wagman,S. Cummings

10.10Auditorium 1

OC5THE PHASE 3 COMPARISON OF RALOXIFENE ANDLASOFOXIFENE (CORAL) TRIAL: CHANGES IN BONEMARKERS AND BONE MINERAL DENSITYPresenting author: M. R. McClungAuthors: J. Symons, D. Portman

10.20Auditorium 1

OC6A RANDOMIZED CONTROLLED TRIAL OF SCREENINGIN THE COMMUNITY TO REDUCE FRACTURES INOLDER WOMEN IN THE UK (THE SCOOP STUDY)Presenting author: L. ShepstoneAuthors: E. Lenaghan, S. Clarke, R. Fordham, N. Gittoes,I. Harvey, R. Holland, A. Howe, T. Marshall, E. McCloskey,T. Peters, J. A. Kanis, T. W. O'neill, D. Torgerson

10.30Auditorium 1

Plenary Lecture 2Plenary Lecture 2 - Offset of fracture risk after treatment cessation, a

base for transient treatment interruption -Eugene McCloskey

11.00Auditorium 1

Presentation of the ESCEO-MSD FellowshipsCyrus Cooper, Anne De Papp

11.10Auditorium 1


OC7EFFECT OF ODANACATIB ON BONE DENSITY ANDESTIMATED BONE STRENGTH INPOSTMENOPAUSAL WOMEN: A CT-BASEDSUBSTUDY OF THE PHASE 3 LONG-TERMODANACATIB FRACTURE TRIAL (LOFT)Presenting author: K. EngelkeAuthors: B. L. Langdahl, T. DeVilliers, T. M. Keaveny,H. K. Genant, S. Ather, H. Giezek, A. Lombardi, A. Leung,A. De Papp

11.20Auditorium 1

OC8PREVENTING BONE LOSS UPON STOPPINGDENOSUMAB THERAPY: FINDINGS FROM TWOCLINICAL STUDIESPresenting author: M. R. McClungAuthors: P. Miller, D. L. Kendler, N. Pannacciulli, A. Wang,R. B. Wagman, S. Ferrari

11.30Auditorium 1

OC9PRIOR EXPOSURE TO BISPHOSPHONATESPREVENTS THE REBOUND OF BONE TURNOVERMARKERS AFTER DENOSUMAB THERAPYPresenting author: UebelhartAuthors: R. Rizzoli, S. Ferrari

11.40Auditorium 1

OC10EFFECT OF INVESTIGATIONAL TREATMENTABALOPARATIDE FOR PREVENTION OF MAJOROSTEOPOROTIC FRACTURE OR ANY FRACTURE ISNOT ALTERED BY BASELINE FRACTUREPROBABILITYPresenting author: E. McCloskeyAuthors: N. C. Harvey, A. Odén, H. Jiang, S. Modin,L. A. Fitzpatrick, J. A. Kanis, H. Johansson

11.50Auditorium 1

OC11BONE’S MICROSTRUCTURE AND MATERIALCOMPOSITION ARE COMPROMISED IN WOMENSUFFERING ATYPICAL FEMORAL FRACTURESDURING ANTIRESORPTIVE THERAPYPresenting author: E. SeemanAuthors: R. Zebaze, A. Chiang, H. Nguyen, A. Ghasem‑Zadeh,M.B. Zanchetta, J. R. Zanchetta, P. R. Ebeling

12.00Auditorium 1

OC12RISK FOR HIP FRACTURE TEN YEARS BEFORE ANDAFTER TOTAL KNEE REPLACEMENT SURGERY INTHE ENTIRE SWEDISH POPULATIONPresenting author: C. H. ValaAuthors: J. Kärrholm, S. Sten, M. Karlsson, V. Sundh,M. Lorentzon, Mellström


INDUSTRY-SPONSORED LUNCH SYMPOSIUMINDUSTRY-SPONSORED LUNCH SYMPOSIUM12.15 - 13.45Auditorium 2

INDUSTRY-SPONSORED LUNCH SYMPOSIUMINDUSTRY-SPONSORED LUNCH SYMPOSIUM

8


EDUCATIONAL LECTUREEDUCATIONAL LECTUREAuditorium 2The ABC of writing a manuscript

Ego Seeman

14.00 - 15.00Poster Area

Poster Viewing Session I

14.00 - 15.10Podium

Oral presentation of selected postersChairperson: Johanne Martel‑Pelletier

14.00Podium

P915ACCUMULATED QUALITY OF LIFE LOSS 36 MONTHSAFTER VERTEBRAL AND DISTAL FOREARMFRACTURE: RESULTS FROM ICUROS IN LITHUANIAPresenting author: M. TamulaitieneAuthors: V. Alekna, F. Borgström, V. Sinkeviciene, A. Svedbom,R. Stukas, J. A. Kanis

14.07Podium

P836VERTEBRAL FRACTURE RISK: ALENDRONATETREATMENT ENHANCES ANTERIORMICROSTRUCTURE IN OSTEOPOROTIC VERTEBRAEPresenting author: A. vom ScheidtAuthors: M. Krause, K. Püschel, M. Amling, B. Busse

14.14Podium

P829CATHEPSIN K KNOCKOUT IMPROVES BONE MASSAND SUPPRESSES LONG BONE FRACTURES IN THEOSTEOGENESIS IMPERFECTA MOUSE MODEL (OIM)Presenting author: T. RoelsAuthors: J.‑P. Devogelaer, L. T. Duong, M. Cardinal, C. Behets,D.H. Manicourt

14.21Podium

P822LOW-COST AND EFFICIENT FINITE ELEMENTANALYSIS OF BONE FOR HIGH-RESOLUTIONPERIPHERAL QUANTITATIVE COMPUTEDTOMOGRAPHY DATAPresenting author: L. WarrenAuthors: M. H. Edwards, Z. Au, K. A. Ward, E. M. Dennison,C. Cooper, P. Schneider

14.28Podium

P690IMPACT OF FRACTURE RISK ASSESSMENT TOOLSON PROPORTIONS OF WOMEN WITHOUT PRIORFRACTURE IDENTIFIED AT RISK AND TREATED –LESSONS FROM THE SIGN GUIDANCEPresenting author: E. McCloskeyAuthors: J. E. Compston, C. Cooper, N. C. Harvey,H. Johansson, A. Odén, J. A. Kanis

14.35Podium

P492POST-FRACTURE CARE: DO WE NEED TO EDUCATETHE PATIENTS RATHER THAN THE DOCTORS? THEPREVOST RANDOMIZED CONTROL TRIALPresenting author: B. MerleAuthors: R. D. Chapurlat, E. Vignot, T. Thomas, J. Haesebaert,A.‑M. Schott

14.42Podium

P373REBOUND-ASSOCIATED VERTEBRAL FRACTURESAFTER DENOSUMAB DISCONTINUATION: A SERIESOF 8 WOMEN WITH 35 SPONTANEOUS VERTEBRALFRACTURES.Presenting author: O. LamyAuthors: D. Stoll, E. Gonzalez Rodriguez, D. Hans,B. Aubry‑Rozier

14.49Podium

P155HOW DOES THE INITIAL SLOPE OF THE VARIOGRAM,THE TEXTURAL BASIS OF THE TRABECULAR BONESCORE, PREDICT VERTEBRAL STRENGTH?Presenting author: P. K. ZyssetAuthors: G. Maquer, Y. Lu, E. Dall'Ara, X. Chevalier, M. Krause,L. Yang, R. Eastell, K. Lippuner

14.56Podium

P148THE WNT-INACTIVATING LIPASE NOTUM AS ANOVEL ANABOLIC OSTEOPOROSIS DRUG TARGETPresenting author: R. BrommageAuthors: A. Y. Thompson, M. K. Shadoan, J. Liu,S. Jeter‑Jones, J. Ciu, D. G. Potter, D. Bright, F. Mseeh,J. P. Bardenhagan, G. M. Hansen, P. Vogel, J. E. Tarver,B. Zambrowicz, Q. Liu, D. R. Powell

15.03Podium

P105THE IMPACT OF VITAMIN D, CALCIUM, PROTEINSUPPLEMENTATION, AND PHYSICAL EXERCISE ONBONE METABOLISM AFTER BARIATRIC SURGERY:THE BABS STUDYPresenting author: C. MuschitzAuthors: R. Kocijan, J. Haschka, A. Zendeli, T. Pirker,G. Muschitz, H. Resch, P. Pietschmann

9

14.00 - 15.00MEET-THE-EXPERT SESSIONSMEET-THE-EXPERT SESSIONS

Meeting Room 1General management of osteoarthritis patients

Burkhard Leeb

Meeting Room 2Cancer bone disease

Socrates Papapoulos

Meeting Room 3Management of glucocorticoid-induced osteoporosis

Karel Pavelka

Meeting Room 4Effective control of inflammatory arthritis

Tore Kvien

Meeting Room 5Hand osteoarthritis: imaging and management

Emmanuel Maheu

14.00 - 15.00ESCEO SYMPOSIAESCEO SYMPOSIA

Conference Room 2.1

Critical analysis of currently availableorthopaedic procedures to increase bone mass,structure and strength through intra-osseousinterventions

Chairpersons: Andreas Kurth, Dominique Pioletti

- Welcome and scope of the problem - Serge Ferrari

- Current and new tools to assess hip bone strength -Philippe K. Zysset

- Challenges and opportunities for drug therapies inpreventing hip fractures - Serge Ferrari

- Currently available orthopaedic procedures for boneenhancement - Andreas Kurth

- Discussion - Leader: Maria Luisa Brandi

- Wrap-up - Serge Ferrari

- Adjournment of the meeting - John A. KanisPanel: Maria Luisa Brandi, Serge Ferrari, John A. Kanis,Andreas Kurth, Andrea Laslop, Socrates Papapoulos,Dominique Pioletti, Jean‑Yves Reginster, René Rizzoli,Philippe K. Zysset

Conference Room 2.2

ESCEO algorithm for the treatment ofosteoarthritis – From evidence-based medicineto real-life setting

Chairpersons: Johanne Martel‑Pelletier, Cyrus Cooper

- Welcome address - Jean‑Yves Reginster

- Efficacy and safety of glucosamine sulfate in themanagement of osteoarthritis: evidence from real-life setting trials and surveys - Jean‑Yves Reginster

- Efficacy and safety of oral and topical NSAIDs plusanalgesics in the management of osteoarthritis:evidence from real-life setting trials and surveys -Jean‑Pierre Pelletier

- Efficacy and safety of hyaluronic acid in themanagement of osteoarthritis: evidence from real-life setting trials and surveys - François Rannou

- Discussion leaders - Olivier Bruyère, Jaime Branco

- Wrap-up and conclusions - Cyrus CooperPanel: Jaime Branco, Maria Luisa Brandi, Olivier Bruyère,Cyrus Cooper, Marc Hochberg, John A. Kanis, Tore Kvien,Emmanuel Maheu, Johanne Martel‑Pelletier,Jean‑Pierre Pelletier, François Rannou,Jean‑Yves Reginster, René Rizzoli


SCIENTIFIC SESSION IISCIENTIFIC SESSION IIChairpersons: Maria Luisa Brandi, René Rizzoli

15.00Auditorium 1

Plenary Lecture 3Plenary Lecture 3 - Successful musculoskeletal ageing -

Jonathan D. Adachi

15.30Auditorium 1

Presentation of the IOF President's AwardsJohn A. Kanis

15.40Auditorium 1


OC13CORTICAL POROSITY IDENTIFIES WOMEN WITHOUTOSTEOPOROSIS SUFFERING FRAGILITY FRACTURES:THE PROSPECTIVE OFELY STUDYPresenting author: S. BoutroyAuthors: R. Zebaze, E. Sornay‑Rendu, E. Seeman,R. D. Chapurlat

10

15.50Auditorium 1

OC14BONE MATERIAL STRENGTH INDEX IN PATIENTSWITH LOW BONE MASS AND FRAGILITY FRACTURESPresenting author: F. MalgoAuthors: S. Papapoulos, N. A. T. Hamdy,N. M. Appelman‑Dijkstra

16.00Auditorium 1

OC15RISK AND PREDICTORS OF SUBSEQUENTFRACTURES AFTER AN ATYPICAL FEMORALFRACTUREPresenting author: E. BiverAuthors: M.‑C. Audet, R. Peter, R. Meier, Uebelhart,T. Chevalley, K. I. Lorenzini, R. Rizzoli, S. Ferrari

16.10Auditorium 1

OC16LONGITUDINAL CHANGES IN BONE STRUCTURE ASASSESSED BY PERIPHERAL QUANTITATIVECOMPUTED TOMOGRAPHY AND RELATIONSHIPSWITH MUSCLE HEALTH IN OLDER MEN AND WOMENPresenting author: M. H. EdwardsAuthors: K. A. Ward, K. Jameson, E. M. Dennison, C. Cooper

16.20Auditorium 1

OC17RELATIONSHIP BETWEEN TOTAL HIP BMD T-SCOREAND INCIDENCE OF NONVERTEBRAL FRACTUREWITH UP TO 10 YEARS OF DENOSUMAB (DMAB)TREATMENTPresenting author: S. FerrariAuthors: S. Adami, J. P. Brown , F. Cosman, E. Czerwinski,L. H. De Gregório, J. Malouf, J.‑Y. Reginster, N. S. Daizadeh,A. Wang, R. B. Wagman, E. M. Lewiecki

16.30Auditorium 1

Plenary Lecture 4Plenary Lecture 4 - Clinical guidelines for the management of

osteoarthritis - Cyrus Cooper


INDUSTRY-SPONSORED SATELLITEINDUSTRY-SPONSORED SATELLITESYMPOSIUMSYMPOSIUM17.00 - 18.30Auditorium 1

INDUSTRY-SPONSORED SATELLITEINDUSTRY-SPONSORED SATELLITESYMPOSIUMSYMPOSIUM

11


Meeting Room 1

Cancer treatment induced bone loss (CTIBL) inwomen with breast cancer

Chairpersons: Peyman Hadji, René Rizzoli

- Risk factors for fractures in women with breastcancer - Jean‑Jacques Body

- Current treatment guidelines and interventionoptions - Peyman Hadji

- Additive effects of antiresorptive treatments beyondosteoporosis - Robert E. Coleman

Meeting Room 2

The clinical value of bone turnover markerassays: latest developments from the IFCC-IOFworking group and NBHA

Chairperson: Taylor C. Wallace

- Welcome - Taylor C. Wallace

- Pathophysiology and variability of bone turnovermarkers - Howard Morris

- Standard reference markers – clinical role andresearch goals for harmonization andstandardization - Stuart Silverman

- IOF and IFCC harmonization of bone turnovermarkers - Howard Morris

- NBHA bone turnover marker standardization project- Stuart Silverman

- Question and answer session - Taylor C. Wallace

- Conclusion - Taylor C. Wallace

Meeting Room 3

DXA Pitfalls and Tips: FRAX and TBS Integrationinto acquisition and analysis routine

Chairperson: Bruno Muzzi Camargos

- Dual X-Ray absorptiometry basic principles -Ben‑Hur Albergaria

- FRAX - Cristiano A. F. Zerbini

- TBS - Bruno Muzzi Camargos

Meeting Room 4

Frailty, Falls and Fractures: identification andtreatment of the dysmobility syndrome in olderpersons

Chairperson: Neil Binkley

- Muscle and bone interactions: the biology ofosteosarcopenia and dysmobility - Gustavo Duque

- Potential clinical approaches to the diagnosis ofosteosarcopenia/dysmobility - Neil Binkley

- Therapeutic interventions for osteosarcopenia:current evidence and future directions -Cristina Alonso Bouzon

Meeting Room 5

FRAX International experience with aninternational tool

Chairperson: John A. Kanis

- Introduction - FRAX in the world today - John A. Kanis

- Frax in USA - How FRAX influenced the wayclinicians treat osteoporosis - Michael R. McClung

- Frax in Latin America - An evaluation of FRAX inLatin America - Should we make calibration fordifferent races? - Patricia Clark

- FRAX in Europe - Development and the next steps -Eugene McCloskey


SCIENTIFIC SESSION IIISCIENTIFIC SESSION IIIChairpersons: Olivier Bruyère, Eugene McCloskey

09.00Auditorium 1

Plenary Lecture 5Plenary Lecture 5 - Vitamin D, immune response and infection -

Peter R. Ebeling

09.30Auditorium 1

Presentation of the IOF Medal of AchievementCyrus Cooper

09.40Auditorium 1


OC18VITAMIN D MEASUREMENT STANDARDIZATION:THE WAY OUT OF THE CHAOSPresenting author: N. BinkleyAuthors: B. Dawson‑Hughes, R. Durazo‑Arvizu, M. Thamm,J. Merkel, C. T. Sempos

09.50Auditorium 1

OC19DETERMINANTS OF THE MATERNAL RESPONSE TOVITAMIN D SUPPLEMENTATION DURINGPREGNANCY: THE MAVIDOS TRIALPresenting author: N. C. HarveyAuthors: R. J. Moon, S. D'angelo, S. R. Crozier,I. Schoenmakers, N. J. Bishop, S. Kennedy,A. T. Papageorghiou, R. Fraser, S. V. Gandhi, A. Prentice,C. Cooper, M. K. Javaid

12

10.00Auditorium 1

OC20EFFICACY OF ODANACATIB IN POSTMENOPAUSALWOMEN WITH OSTEOPOROSIS: SUBGROUPANALYSES OF DATA FROM THE PHASE 3 LONG-TERM ODANACATIB FRACTURE TRIAL (LOFT)Presenting author: K. G. SaagAuthors: P. Alexandersen, C.‑L. Benhamou, N. Gilchrist,J. Halse, E. M. Lewiecki, K. Lippuner, M. R. McClung,M. Shiraki, C. A. DaSilva, N. Verbruggen, B. B. Scott,A. Lombardi

10.10Auditorium 1

OC21DYSMOBILITY SYNDROME AND MORTALITY RISK INOLDER CHILEAN PEOPLEPresenting author: C. AlbalaAuthors: L. Lera, B. Angel, H. Sanchez, C. Marquez, P. Arroyo

10.20Auditorium 1

OC22EFFECT OF TREATMENT ON BACK PAIN AND BACKEXTENSOR STRENGTH WITH A SPINAL ORTHOSIS INELDERLY WOMEN WITH OSTEOPOROSIS: ARANDOMIZED CONTROLLED TRIALPresenting author: K. Kaijser AlinAuthors: A.‑L. Grahn Kronhed, E. Uzunel, H. Alinaghizadeh,H. Salminen

10.30Auditorium 1

OC23BASELINE AND PERSISTENT KNEE SYMPTOMS AREINDEPENDENT PREDICTORS OF STRUCTURALPROGRESSION OF KNEE OSTEOARTHRITISPresenting author: J. Martel‑PelletierAuthors: A. J. Teichtahl, F. Cicuttini, Y. Wang, F. Abram,J.‑P. Pelletier

10.40Auditorium 1

Plenary Lecture 6Plenary Lecture 6 - Diabetoporosis and fat tissues - Serge Ferrari

11.10Auditorium 1


OC24THE FUTURE PREVALENCE OF SARCOPENIA INEUROPEPresenting author: O. EthgenAuthors: C. Tchokonte, C. Beaudart, F. Buckinx,J.‑Y. Reginster, O. Bruyère

11.20Auditorium 1

OC25SARCOPENIA DEFINITION PARAMETERS ANDINCIDENT DISABILITYPresenting author: L. A. SchaapAuthors: E. M. Simonsick, A. B. Newman, A. V. Schwartz,P. Caserotti, S. B. Kritchevsky, B. H. Goodpaster, T. B. Harris,M. Visser

11.30Auditorium 1

OC26ASSESSMENT OF MUSCLE/LEAN MASSMEASUREMENT: COMPARISON OF METHODS FORSARCOPENIA DETERMINATIONPresenting author: N. BinkleyAuthors: B. Buehring, E. Fidler, Y. Yamada, D. Krueger,M. Shankaran, G. Czerwieniec, C. Fessler, W. Evans, S. Turner,M. Hellerstein, D. Schoeller

11.40Auditorium 1

OC27AMONG ADULTS AGED 50-64 YEARS, FRAILTY ANDSARCOPENIA ARE IMPORTANTLY ASSOCIATEDWITH PREMATURE WORKLESSNESSPresenting author: Walker‑BoneAuthors: K. T. Palmer, D. Coggon, S. D'angelo, A. A. Sayer,C. Cooper, C. Linaker, E. C. Harris

11.50Auditorium 1

OC28PREVALENCE OF SARCOPENIA IN A POPULATION OFNURSING HOME RESIDENTS ACCORDING TO THEIRFRAILTY STATUS: RESULTS OF THE SENIORCOHORTPresenting author: F. BuckinxAuthors: J.‑Y. Reginster, C. Beaudart, J. L. Croisier,J. Petermans, O. Bruyère

12.00Auditorium 1

OC29EVALUATION OF THE INTRA-INDIVIDUALVARIABILITY OF MYOSTATIN AND ACTIVIN A, TWOBIOMARKERS OF SARCOPENIA: IMPACT ON THELEAST SIGNIFICANT CHANGE AND FOLLOW-UP OFTHE PATIENTSPresenting author: E. CavalierAuthors: C. Piron, F. Watar, S. Kovacs, C. Beaudart,F. Buckinx, O. Bruyère, C. Le Goff, J.‑Y. Reginster

13


INDUSTRY-SPONSORED LUNCH SYMPOSIUMINDUSTRY-SPONSORED LUNCH SYMPOSIUM12.15 - 13.45Auditorium 2

INDUSTRY-SPONSORED LUNCH SYMPOSIUMINDUSTRY-SPONSORED LUNCH SYMPOSIUM

14.00 - 15.00Poster Area

Poster Viewing Session II

14.00 - 15.10Podium

Oral presentation of selected postersChairperson: Johanne Martel‑Pelletier

14.00Podium

P899SUN EXPOSURE, SKIN COLOR AND VITAMIN DSTATUS IN ARAB CHILDREN AND ADULTSPresenting author: Y. Al‑SalehAuthors: N. Al‑Daghri, N. Khan, S. Sabico, N. Aljohani,H. Alfawaz, M. Alsulaimani, A. Al‑Othman, M. alokail

14.07Podium

P311CALCIUM AND VITAMIN D SUPPLEMENTATION ARENOT ASSOCIATED WITH INCREASED RISK OFISCHAEMIC CARDIAC EVENTS: RESULTS FROM UKBIOBANKPresenting author: N. C. HarveyAuthors: S. D'angelo, J. Paccou, M. H. Edwards, S. E. Petersen,C. Cooper

14.14Podium

P653NEW CARTILAGE QUALITY EVALUATION USINGCYCLIC NANO INDENTATION: CASE STUDY WITH ATOOL DMOAD COMPOUND ACTIVE IN THE RAT MNXMODELPresenting author: C. LavetAuthors: P. Clement‑Lacroix, D. Merciris, S. Meurisse,L. Lespecheux, V. Gaillard, P. Pastoureau, P. Deprez,D. Amantini, P. Ammann

14.21Podium

P561REFERENCE POINT MICROINDENTATION FORSUPPLEMENTING FRACTURE RISK ASSESSMENT ATTHE FEMORAL NECKPresenting author: P. J. ThurnerAuthors: T. Jenkins, L. V. Coutts, S. D'angelo, D. G. Dunlop,R. O. C. Oreffo, C. Cooper, N. C. Harvey

14.28Podium

P438PRIMARY CULTURES OF HUMAN SKELETAL MUSCLESATELLITE CELLS: A NOVEL MODEL TO ASSESSSKELETAL MUSCLE CELL DIFFERENTIATIONPresenting author: L. CianferottiAuthors: C. Romagnoli, M. Vigna, R. Zonefrati, C. Mavilia,G. Galli, M. Innocenti, G. Marcucci, A. Tanini, M. L. Brandi

14.35Podium

P387AGE-RELATED TRAJECTORIES OF MUSCLE MASSAND FUNCTION IN ITALIAN COMMUNITY-DWELLERSVISITING THE MILAN EXPO: RESULTS FROM THE VIPSTUDYPresenting author: M. TosatoAuthors: R. Calvani, E. Marzetti, G. Savera, A. Collamati,A. Sisto, E. Ortolani, A. M. Martone, R. Bernabei, F. Landi

14.42Podium

P379ENGLISH TRANSLATION AND CROSS-CULTURALADAPTATION OF THE SARQOL® QUESTIONNAIREPresenting author: C. BeaudartAuthors: M. H. Edwards, E. M. Dennison, C. Moss, O. Bruyère,J.‑Y. Reginster, R. J. Moon, C. Cooper, C. Demoulin

14.49Podium

P367SARCOPENIA AND HIGH RISK OF NONVERTEBRALFRACTURE IN OLDER MEN: THE STRAMBO STUDYPresenting author: P. SzulcAuthor: R. D. Chapurlat

14.56Podium

P325MUSCLE MASS PREDICTS INCIDENT FRACTURE INPOSTMENOPAUSAL WOMEN: THE OFELY STUDYPresenting author: E. Sornay‑RenduAuthors: F. Duboeuf, S. Boutroy, R. D. Chapurlat

15.03Podium

P250A COMPARATIVE STUDY OF THE EFFECTS OF PTHFORMULATIONS ON JAPANESE PATIENTS WITHOSTEOPOROSISPresenting author: H. KikuchiAuthors: Y. Itoh, W. Shimada, N. Okada, S. Soen

14

14.00 - 15.00ESCEO SYMPOSIAESCEO SYMPOSIA

Conference Room 2.1

Biological and imaging (MRI, DXA,…) markers inthe assessment and management ofsarcopenia in daily practice

Chairpersons: Yves Rolland, Roger Fielding

- Welcome and Introduction - Roger Fielding

- Evaluation of the sarcopenic patients: The role ofprimary versus secondary care physicians -Antonio Cherubini

- Role of markers in the assessment andmanagement of sarcopenia in daily practice:presentation of the ESCEO Experts Consensus -Matteo Cesari

- Discussion - Leader: Francesco LandiPanel: Islene Araujo de Carvalho, Jurgen Bauer,Ivan Bautmans, Charlotte Beaudart, Maria Luisa Brandi,Olivier Bruyère, Nansa Burlet, Etienne Cavalier,Francesca Cerreta, Matteo Cesari, Antonio Cherubini,Cyrus Cooper, Alfonso Cruz Jentoft, Roger Fielding,Evelien Gielen, John A. Kanis, Jean‑Marc Kaufman,Francesco Landi, Andrea Laslop, Eugene McCloskey,Jean Petermans, Jean‑Yves Reginster, René Rizzoli,Yves Rolland, Marjolein Visser

Conference Room 2.2

Diacerein in the management of osteoarthritis:facts or fantasy

Chairpersons: Jordi Monfort, Karel Pavelka

- Welcome - Jordi Monfort

- Preclinical evidence supporting the mode of actionof diacerein in osteoarthritis - Johanne Martel‑Pelletier

- Efficacy of diacerein in the management ofosteoarthritis - Burkhard Leeb

- Safety and risk/benefit ratio of diacerein in themanagement of osteoarthritis - Jean‑Pierre Pelletier

- Discussion - Leader: Emmanuel Maheu

- Conclusions - Karel PavelkaPanel: Olivier Bruyère, Cyrus Cooper, John A. Kanis,Burkhard Leeb, Johanne Martel‑Pelletier, Jordi Monfort,Karel Pavelka, Jean‑Pierre Pelletier, Jean‑Yves Reginster,René Rizzoli

14.00 - 15.00MEET-THE-EXPERT SESSIONS (supported byMEET-THE-EXPERT SESSIONS (supported byan unrestricted educational grant from UCBan unrestricted educational grant from UCBBiopharma)Biopharma)

Meeting Room 1Can we have targets in osteoporosis treatment?

Serge Ferrari

Meeting Room 2Bone strength assessment for the non-initiated

Philippe K. Zysset

Meeting Room 3Is Sclerostin an appropriate target for the treatment ofosteoporosis?

Michael R. McClung

Meeting Room 4Post-fracture care

Andreas Kurth

Meeting Room 5Secondary osteoporosis

Jaime Branco

Meeting Room 6Rare bone diseases

Maria Luisa Brandi


SCIENTIFIC SESSION IVSCIENTIFIC SESSION IVChairpersons: Cyrus Cooper, Jean‑Marc Kaufman

15.00Auditorium 1

Plenary Lecture 7Plenary Lecture 7 - Diet, microbiome and bone - René Rizzoli

15.30Auditorium 1

Presentation of the ESCEO-AgNovos HealthcareYoung Investigator Awards

Maria Luisa Brandi, James Howe

15.40Auditorium 1


OC30DISTAL RADIUS CORTICAL MICROSTRUCTURE ANDCALCULATED STRENGTH PREDICT INCIDENTFRACTURES INDEPENDENTLY OF FRAX INPOSTMENOPAUSAL WOMENPresenting author: E. BiverAuthors: C. Durosier, T. Chevalley, B. van Rietbergen,R. Rizzoli, S. Ferrari

15

15.50Auditorium 1

OC31SWEDISH FARMERS HAVE LOWER RISK FOR HIPFRACTURE THAN EXPECTED FROM ECONOMICSTATUS, EDUCATION AND LOCATIONPresenting author: H. JohanssonAuthors: C. H. Vala, A. Odén, M. Lorentzon, E. McCloskey,J. A. Kanis, S. Lohmander, J. Kärrholm, Mellström

16.00Auditorium 1

OC32WITHIN AND ACROSS-SEX INHERITANCE OF BONEMICROARCHITECTUREPresenting author: J. PepeAuthors: E. Biver, N. Bonnet, T. Chevalley, R. Rizzoli, S. Ferrari

16.10Auditorium 1

OC33IMMINENT FRACTURE RISK IN ELDERLYOSTEOPOROTIC WOMEN: UNDERLYINGRELATIONSHIPS BETWEEN RISK FACTORS ANDOUTCOMEPresenting author: D. WeyckerAuthors: A. Kartashov, J. Edelsberg, J. Lani, A. Grauer,D. B. Crittenden, R. Barron

16.20Auditorium 1

OC34FEMORAL NECK BMD IS STILL THE PREFERRED SITEIN THE ASSESSMENT OF HIP FRACTURE IN ELDERLYMEN (10-YEAR FOLLOW-UP OF MROS SWEDEN)Presenting author: H. JohanssonAuthors: A. Odén, M. K. Karlsson, M. Lorentzon, J. A. Kanis,B. Rosengren, Mellström, O. Ljunggren, C. Ohlsson,N. C. Harvey, E. McCloskey

16.30Auditorium 1

Plenary Lecture 8Plenary Lecture 8 - Defining sarcopenia - Bess Dawson‑Hughes

15.00 - 16.50Conference Room 2.2

COMMITTEE OF NATIONAL SOCIETIESCOMMITTEE OF NATIONAL SOCIETIESSPECIAL PLENARY SESSIONSPECIAL PLENARY SESSION

Advances in Bone, Muscle and Joint Health15.03Conference Room 2.2

OCs1HYPOVITAMINOSIS D IN A YEAR-ROUND SUNNYAREA: OUTDOORS AND INDOORS LIFESTYLEPERSPECTIVESPresenting author: H. M. Al Attia

15.11Conference Room 2.2

OCs2CAMURATI-ENGELMANN DISEASE WITH SPINALCORD COMPRESSION: CASE REPORT ANDASSESSMENT OF BONE MICROARCHITECTURE BYHR-PQCTPresenting author: C. R. UnaAuthors: M.B. Zanchetta, J. J. Rivero, F. O. Rodriguez,J. R. Zanchetta, O. D. Messina


OCs3REFRACTURE RATE IN FLS IN RIO DE JANEIROPresenting author: B. StolnickiAuthors: R. Galdino, R. Melo, A. Libman, H. Maleh


OCs4EFFECT OF MINODRONATE IN PATIENTS WITH LOWBONE MINERAL DENSITY GAIN WHILE USING OTHERBISPHOSPHONATESPresenting author: H. H. HaginoAuthors: K. Kita, J. Takada, N. Yamagata, M. Ishii


OCs5PRE-SARCOPENIA, SARCOPENIA, CACHEXIA ANDOSTEOPOROSIS IN PATIENTS WITH ANKYLOSINGSPONDYLITISPresenting author: A. El MaghraouiAuthors: F. E. Bertin, S. Sadni, A. Majjad, T. Hamza,A. Mounach


OCs6AXIAL BMD IN SOUTH EAST ASIAN PATIENTS WITHTYPE 2 DM: HOW DO RACE AND BMI MATTER?Presenting author: M. ChandranAuthors: Y. Hao, M. Tan, D. Tay


OCs7THE ASSOCIATIONS BETWEEN FEAR OF FALLING,FUNCTIONAL ABILITY AND MUSCLE MASS IN THEELDERLYPresenting author: A. MastaviciuteAuthors: A. Versalovic, I. Tamulaityle‑Morozoviene,M. Tamulaitiene, V. Alekna

16


OCs8GENDER DIFFERENCES IN PATIENT INVOLVEMENTIN OSTEOPOROSIS CAREPresenting author: A. I. GasparikAuthors: D. M. Farcas, M. L. Cevei


OCs9ASSOCIATION BETWEEN LEAN MASS ANDDIETARY PROTEIN INTAKE IN POSTMENOPAUSALWOMENPresenting author: V. V. PovoroznyukAuthors: N. I. Dzerovych, R. V. Povoroznyuk


OCs10CHANGES IN QUALITY OF LIFE AFTER FRAGILITYHIP FRACTURES, THAILANDPresenting author: T. SangkomamhangAuthor: U. Sangkomamhang


OCs11THE PREVALENCE OF UNEXPLAINED HBMAMONGST A DXA POPULATION IN ANOSTEOPOROSIS REFERENCE CENTRE FROMROMANIAPresenting author: D. GrigorieAuthor: A. Sucaliuc


OCs12THE INFLUENCE OF OSTEOPOROSIS ON WELL-BEING IN MENPresenting author: D. M. FarcasAuthors: L. Sachelarie, A. I. Gasparik


Presentation of the IOF Committee of NationalSocieties Medal


17.00 - 18.30INDUSTRY-SPONSORED SATELLITEINDUSTRY-SPONSORED SATELLITESYMPOSIUMSYMPOSIUM

17.00 - 18.30INDUSTRY-SPONSORED SATELLITEINDUSTRY-SPONSORED SATELLITESYMPOSIUMSYMPOSIUM

17.00 - 18.30ESCEO-IOF-EUGMS-ESPEN SYMPOSIUM - byESCEO-IOF-EUGMS-ESPEN SYMPOSIUM - byinvitation onlyinvitation onlyCohort working group

18.30 - 19.30Cocktail offered by IOF and ESCEO to all recipientsof prizes, awards, fellowships and scholarships - byinvitation only

17


Meeting Room 1

Muscular training for patients with vertebralfractures

Chairperson: Dan Mellström

- Vertebral fractures in an orthopaedic perspective -Paul Gerdhem

- Sarcopenia and osteoporosis – the hazardous duo -Tommy Cederholm

- Vertebral fractures in an osteoporotic perspective,symptoms and what to do - Ingrid Bergström

- Training program presentation - Anna Dahlgren

Meeting Room 2

Risk of osteoporosis in inflammatory rheumaticdiseases

Chairpersons: Mislav Radić, Jasminka Milas Ahić,Dušanka Martinović Kaliterna

- Pathophysiology of osteoporosis in inflammatoryrheumatic diseases - Jasminka Milas Ahić

- Risk of osteoporosis in inflammatory rheumaticdiseases - Mislav Cerovec

- Osteorheumatology - current knowledge andperspective - Mislav Radić

Meeting Room 3

Optimizing treatment outcomes in osteoporosis:patients’ preferences and involvement in clinicaldecision making

Chairperson: Mickaël Hiligsmann

- Introduction to medication adherence, preferenceand shared-decision making - Mickaël Hiligsmann

- Patients’ preferences for osteoporosis drugtreatment (review) - Sandrine Bours

- From groups to individuals: from preference studiesto shared decision making in the clinical setting -Annelies Boonen

- General discussionMeeting Room 4

IOF-FFN: After the fracture - what does thepatient need?

Chairpersons: Karsten Dreinhöfer, Kassim Javaid

- Acute perioperative management - Paolo Falaschi

- Fracture surgery - Kristina Åkesson

- Post-acute care – rehabilitation - Karsten Dreinhöfer

- Capture the Fracture - Cyrus Cooper

Meeting Room 5

Clinical conundrums in osteoporosismanagement

Chairpersons: Karen Walker‑Bone, Elaine M. Dennison- Assessment of fracture risk in practice - Case presentation - Karen Walker‑Bone

- Discussion - Elaine Dennison, Cyrus Cooper- Fracture despite bisphosphonates - Case presentation - Karen Walker‑Bone

- Discussion - Elaine M. Dennison- Fracture prevention in patients with gastro-oesophageal reflux - Case presentation - Karen Walker‑Bone

- Discussion - Elaine M. Dennison- Atypical fracture - Case presentation - Karen Walker‑Bone

- Discussion - Elaine M. Dennison

Meeting Room 6

Body composition reference values amongLatin America population. Argentina, Brazil andMexico Results.

Chairperson: Osvaldo D. Messina

- Sarcopenia: pathophysiology, assessment anddiagnosis - Osvaldo D. Messina

- Postmenopausal women with sarcopenia havehigher prevalence of osteoporotic fractures -Maria Belen Zanchetta

- Prevalence of sarcopenia and associated riskfactors by two diagnostic criteria in community-dwelling older women: the São Paulo Ageing &Health Study (SPAH) - Rosa Maria Pereira

- Total and appendicular lean body mass referencevalues by dual-energy X-ray absorptiometry amonghealthy Mexican population - Patricia Clark

- Q&A - Presentation of "Sergio Ragi" Award - Presentation of Awarded Abstract

18

09.00 - 10.00MEET-THE-EXPERT SESSIONSMEET-THE-EXPERT SESSIONS

Meeting Room 1How to improve muscle function in the elderly: factand fantasy

Ivan Bautmans

Meeting Room 2Intra-articular therapies

François Rannou

Meeting Room 3Which osteoporotic patients should be treated inLatin America

Patricia Clark

Meeting Room 4Structure modifying treatments of OA

Jean‑Pierre Pelletier


SCIENTIFIC SESSION VSCIENTIFIC SESSION VChairpersons: Bess Dawson‑Hughes, Nicholas Harvey

10.00Auditorium 2

Plenary Lecture 9Plenary Lecture 9 - Novel targets and therapies in osteoporosis -

Socrates Papapoulos

10.30Auditorium 2

Presentation of the IOF Olof Johnell ScienceAward

Bess Dawson‑Hughes

10.40Auditorium 2

Presentation of the 2016 IOF-ESCEO PierreMeunier Young Scientist Awards

René Rizzoli

10.50Auditorium 2


OC35IMMINENT RISK OF MAJOR OSTEOPOROTICFRACTURE AFTER FRACTURE (REYKJAVIK STUDY)Presenting author: N. C. HarveyAuthors: H. Johansson, K. Siggeirsdottir, A. Odén,V. Gudnason, E. McCloskey, G. Sigurdsson, J. A. Kanis

11.00Auditorium 2

OC36PRIOR FRAGILITY FRACTURE PREDICTSCARDIOVASCULAR EVENTS IN MEN: RESULTSFROM UK BIOBANKPresenting author: J. PaccouAuthors: S. D'angelo, M. H. Edwards, C. Cooper,S. E. Petersen, N. C. Harvey

11.10Auditorium 2

OC37A SIMULATION MODEL FOR THE TREATMENTPATHWAY OF OSTEOPOROSISPresenting author: F. BorgströmAuthors: G. Olafsson, E. Jonsson, O. Ström, O. Ljunggren,K. Åkesson, A. Spangeus, J. A. Kanis

11.20Auditorium 2

OC38ANTI-OSTEOPOROSIS MEDICATION PRESCRIPTIONSAND INCIDENCE OF SECONDARY FRACTUREAMONGST PRIMARY HIP FRACTURE PATIENTS INENGLAND AND WALES: AN INTERRUPTED TIMESERIES AND ECONOMIC ANALYSISPresenting author: S. HawleyAuthors: J. Leal, A. Delmestri, D. Prieto‑Alhambra, N. K. Arden,C. Cooper, M. K. Javaid, A. Judge

11.30Auditorium 2

OC39QUALITY OF LIFE UP TO 18 MONTHS AFTER DISTALFOREARM FRACTURE: RESULTS FROM THE ICUROSPresenting author: A. SvedbomAuthors: E. Hernlund, V. Alekna, M. L. Bianchi, P. Clark,M. Diaz‑Curiel, H. P. Dimai, O. M. Lesnyak, E. McCloskey,K. M. Sanders, S. L. Silverman, M. Tamulaitiene, T. Thomas,A. Tosteson, F. Borgström, J. A. Kanis

11.40Auditorium 2

OC40FRACTURE INCIDENCE IN THE UNITED KINGDOM1988-2012: VARIATION BY AGE, SEX, GEOGRAPHY,ETHNICITY AND SOCIOECONOMIC STATUSPresenting author: E. M. CurtisAuthors: R. van der Velde, R. J. Moon, C. E. Wyers,J. P. van den Bergh, P. Geusens, F. De Vries, T. Van Staa,C. Cooper, N. C. Harvey

11.50Auditorium 2

Plenary Lecture 10Plenary Lecture 10 - The paradox of target to treat versus treat to target -

John A. Kanis

12.30End of the CongressEnd of the Congress

19

THURSDAY, APRIL 1419.55 - 20.55Teatro Cervantes

MEDA AB WELCOME COCKTAILMEDA AB WELCOME COCKTAIL

FRIDAY, APRIL 1512.15 - 13.45Auditorium 1

MEDA AB LUNCH SYMPOSIUMMEDA AB LUNCH SYMPOSIUMUnsolved questions in the management of osteoarthritis

Chairpersons: Cyrus Cooper, Jean‑Yves Reginster

- Introduction - Jean‑Yves Reginster

- Glucosamine sulfate: from pharmacokinetics toclinical effectiveness - the need for distinctions -Olivier Bruyère

- A critical review of the evidence on the use ofglucosamine in osteoarthritis: a novel aspect ofevidence-based research - Robin Christensen

- "Closing the circle": publication of the real-lifeevidence - Lucio C. Rovati

- Conclusions and discussion


ELI LILLY LUNCH SYMPOSIUMELI LILLY LUNCH SYMPOSIUMNovel Bone Quality Assessment Measures for Advancingthe Management of Osteoporosis

- Welcome and Introduction - Assessment of Bone Tissue Properties Using Micro-

indentation: State-of-the-art - Teriparatide Effects on Human Bone Tissue: Recent

Results From the SHOTZ and AVA ActiveComparator Trials

- Q&A and Closing Remarks


AMGEN SATELLITE SYMPOSIUMAMGEN SATELLITE SYMPOSIUMLong-term benefits of osteoporosis therapy – evaluatingthe evidence

Chairperson: Adolfo Diez‑Perez

- Welcome and introduction - Adolfo Diez‑Perez

- Long-term treatment of osteoporosis: insights fromclinical trials - Socrates Papapoulos

- A decade of BMD gains: what are the clinicalbenefits? - Serge Ferrari

- Navigating the treatment pathway: real-lifeexperience - Cyrus Cooper

- Panel discussion


ABBOTT SATELLITE SYMPOSIUMABBOTT SATELLITE SYMPOSIUMNew Evidence on the Role of Specialised Nutrition inImproving Patient Outcomes

- The role of lean body mass - Carolyn Grieg

- Evidence on the use of oral nutritional supplementsto improve patient outcomes - Alfonso Cruz Jentoft

- New evidence from the NOURISH study -Nicolaas Deutz

- Panel Discussion / Q&A

SATURDAY, APRIL 1612.15 - 13.45Auditorium 1

MSD LUNCH SYMPOSIUMMSD LUNCH SYMPOSIUMEvolving Treatment Strategies for Osteoporosis:Signalling a Change in the Conversation

Chairperson: Esteban Jodar

- Welcome and opening remarks - Esteban Jodar

- The role of cathepsin K in bone homeostasis -Socrates Papapoulos

- High resolution bone imaging and what it tells usabout predicted bone strength - Angela M. Cheung

- Clinical benefits of osteoporosis therapy -Kenneth G. Saag

- Panel discussion/Q&A


CERIN-EMF-GDP LUNCH SYMPOSIUMCERIN-EMF-GDP LUNCH SYMPOSIUMProteins and sarcopenia: a review of evidence

Chairpersons: Jean‑Yves Reginster, René Rizzoli

- Understanding sarcopenia: causes, mechanismsand consequences - Alfonso Cruz Jentoft

- Dairy protein and muscle mass maintenance:preventing sarcopenia - Lex Verdijk

- Osteosarcopenia: cross-talking between muscle andbone - Véronique Coxam

17.00 - 18.30AVAILABLE SATELLITE SYMPOSIUMAVAILABLE SATELLITE SYMPOSIUM17.00 - 18.30AVAILABLE SATELLITE SYMPOSIUMAVAILABLE SATELLITE SYMPOSIUM

08/02/2016 - 20

world congress on osteoporosis, osteoarthritis and ... · malaga, spain 2016 april 14 - 17...

Documents